The Fort Worth Press - MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

USD -
AED 3.6725
AFN 64.999688
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 918.000363
ARS 1546.728902
AUD 1.47812
AWG 1.8
AZN 1.699085
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.665979
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42779
CDF 2314.999474
CHF 0.839365
CLF 0.025355
CLP 997.910471
CNY 6.67175
CNH 6.67174
COP 3319.96
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.151965
DJF 178.554905
DKK 6.784585
DOP 60.996961
DZD 137.215041
EGP 53.578699
ERN 15
ETB 164.576405
EUR 0.90757
FJD 2.27435
FKP 0.756889
GBP 0.757085
GEL 2.589685
GGP 0.756889
GHS 11.756648
GIP 0.756889
GMD 73.999939
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84515
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.072503
IDR 18245
ILS 3.216701
IMP 0.756889
INR 94.21235
IQD 1520.102326
IRR 1913737.498718
ISK 123.979985
JEP 0.756889
JMD 158.434973
JOD 0.709044
JPY 159.693001
KES 129.760267
KGS 87.435502
KHR 4119.418691
KMF 447.000047
KPW 900.00035
KRW 1335.019976
KWD 0.31147
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.830219
MMK 2100.274506
MNT 3605.662913
MOP 8.103614
MRU 40.552456
MUR 47.620264
MVR 15.396392
MWK 1738.739965
MXN 18.558465
MYR 4.090599
MZN 63.895694
NAD 16.951268
NGN 1343.720245
NIO 36.903315
NOK 9.581275
NPR 151.114437
NZD 1.81148
OMR 0.385095
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.842499
PKR 277.274459
PLN 3.998602
PYG 6223.068898
QAR 3.655265
RON 4.853801
RSD 106.693821
RUB 82.580048
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.875029
SDG 601.50174
SEK 10.078875
SGD 1.288205
SHP 0.752984
SLE 23.050364
SLL 20969.503664
SOS 573.051087
SRD 37.489816
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.841996
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.388901
TTD 6.806306
TWD 32.959096
TZS 2652.559005
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25723.5
VUV 120.320092
WST 2.810586
XAF 595.326965
XAG 0.021074
XAU 0.000258369893
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.326965
XPF 108.186074
YER 236.550142
ZAR 16.956696
ZMK 9001.204398
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084139
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and upcoming initiation of its Phase 1 clinical trial for Ketamir-2, the Company's novel oral ketamine analog in development for neuropathic pain, with subject recruitment scheduled to begin in Q1 2025.

Text size:

The study has received authorization from the Israeli Ministry of Health and the Institutional Review Board (IRB) and will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel. This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers.

The trial consists of two parts:

  • Single Ascending Dose (SAD) Part: 32 participants

  • Multiple Ascending Dose (MAD) Part: 24 participants

In addition to assessing the frequency and severity of adverse events (AEs) and serious adverse events (SAEs), the study will closely evaluate ketamine-related behavioral side effects and assess Ketamir-2's distinct pharmacological profile.

The decision to conduct the study in Israel was made to accelerate timelines and optimize costs, allowing Mira to efficiently allocate resources and extend its operational runway. The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.

Addressing a Large and Unmet Market for Neuropathic Pain

Neuropathic pain is a rapidly growing market, projected to reach $5.2 billion in North America by 2030, driven by an aging population, increasing diabetes prevalence, and chemotherapy-induced nerve damage. Existing treatments, including gabapentin, pregabalin, and opioids, offer only limited relief and carry significant side effects such as sedation, dizziness, addiction, and withdrawal risks. The urgent need for safer, more effective non-opioid therapies presents a significant opportunity for innovation, and Ketamir-2 is uniquely positioned to meet this demand.

Advancing a Safe and Effective Alternative for Neuropathic Pain

MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.

Key Findings from Animal Models:

  • Full Neuropathic Pain Reversal:

    • In a nerve ligation model, Ketamir-2 fully normalized pain thresholds, while oral ketamine had no effect.

  • Superior to FDA-Approved Gabapentin and Pregabalin:

    • In a chemotherapy-induced neuropathy model (PTX), Ketamir-2 restored normal pain sensitivity, outperforming gabapentin by 60%.

    • Up to 112% more effective than pregabalin in reducing neuropathic pain at higher doses.

  • No Hyperlocomotor Activity, Reducing Risk of Behavioral Side Effects:

    • Unlike traditional ketamine, Ketamir-2 did not induce hyperlocomotor activity, a side effect often associated with ketamine's psychotomimetic effects.

  • Optimized for Oral Absorption & Brain Delivery:

    • Not a P-glycoprotein (P-gp) substrate, allowing better absorption and brain penetration.

    • Selective, low affinity NMDA receptor binding reduces dissociative side effects.

  • Enhanced Bioavailability & Prolonged Effect with Nor-Ketamir-2:

    • Nor-Ketamir-2 is the primary active metabolite of Ketamir-2, formed in the body after oral administration.

    • Unlike traditional ketamine, which is rapidly metabolized and cleared, Nor-Ketamir-2 remains in circulation longer, leading to sustained therapeutic effects.

    • The Pamoate salt formulation of Ketamir-2 enhances drug absorption and bioavailability, achieving extended oral bioavailability and higher brain exposure, of nor-ketamir-2 supporting longer-lasting pain relief.

  • Strong Safety Profile:

    • No cardiovascular or respiratory concerns at high doses.

    • High selectivity and cleaner pharmacological profile than traditional ketamine, reducing risks of side effects.

These findings reinforce Ketamir-2's potential as a breakthrough oral treatment for neuropathic pain, offering greater efficacy, improved safety, and convenient administration over existing therapies.

"The neuropathic pain market continues to grow, yet current treatments leave millions of patients without adequate relief," said Erez Aminov, Chairman and CEO of MIRA Pharmaceuticals. "Ketamir-2 has demonstrated remarkable potential in reversing neuropathic pain while maintaining a strong safety profile. With this Phase 1 trial now set to begin, we are moving closer to bringing a much-needed oral treatment to patients suffering from chronic neuropathic pain."

Expanding Research into PTSD and Topical Pain Relief

Beyond neuropathic pain, MIRA Pharmaceuticals is conducting ongoing preclinical studies evaluating Ketamir-2 in PTSD and a potential topical formulation for localized pain relief. These additional indications could significantly broaden the clinical and commercial potential of Ketamir-2.

Dr. Angel, Chief Scientific Advisor at Mira Pharmaceuticals, added: "Ketamir-2 continues to show great promise as we are now ready for the clinical trials. Its strong safety profile and targeted mechanism of action differentiate it from traditional ketamine and other pain treatments, giving us confidence in its potential for multiple indications."

Advancing Mira-55 for Memory Enhancement

In parallel, the Company is assessing Mira-55 for its potential in memory enhancement. This program aligns with MIRA's commitment to neurological innovation, exploring treatments that could address cognitive decline and neurodegenerative conditions.

Regulatory and Development Timeline

With Phase 1 expected to conclude by year-end, Mira is on track to initiate Phase 2a studies in neuropathic pain patients in Q4 2025, further advancing the potential of Ketamir-2 as a novel treatment for neuropathic pain and other neuro indications.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: MIRA Pharmaceuticals



View the original press release on ACCESS Newswire

P.McDonald--TFWP